logo
Novo Nordisk Stock: Is It Still a Smart Buy?

Novo Nordisk Stock: Is It Still a Smart Buy?

Globe and Mail06-06-2025
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete.
I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why.
An increasingly crowded field
Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment.
It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable.
Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success.
Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap.
It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy.
Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest.
Fragmentation and setbacks
Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts.
Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred.
Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy.
One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure.
Fighting back
Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately.
Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy.
Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline.
Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion.
The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market.
Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!*
Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsara to Announce Second Quarter Fiscal Year 2026 Financial Results on September 4, 2025
Samsara to Announce Second Quarter Fiscal Year 2026 Financial Results on September 4, 2025

Globe and Mail

time37 minutes ago

  • Globe and Mail

Samsara to Announce Second Quarter Fiscal Year 2026 Financial Results on September 4, 2025

Samsara Inc. ("Samsara") (NYSE: IOT), the pioneer of the Connected Operations ® Platform, today announced that it will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, after the U.S. market closes on Thursday, September 4, 2025. Samsara will host a live webcast that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results. Event: Samsara's Second Quarter Fiscal Year 2026 Financial Results Date: Thursday, September 4, 2025 Time: 2:00 p.m. Pacific time (5:00 p.m. Eastern time) Webcast: Registration A webcast replay will be accessible from the Samsara investor relations website at The press release will be available on the Samsara investor relations website prior to the commencement of the event. About Samsara Samsara (NYSE: IOT) is the pioneer of the Connected Operations ® Platform, which enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world's leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. The company's mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy.

Pablo Perversi to Join METTLER TOLEDO Board of Directors
Pablo Perversi to Join METTLER TOLEDO Board of Directors

Globe and Mail

time37 minutes ago

  • Globe and Mail

Pablo Perversi to Join METTLER TOLEDO Board of Directors

Mettler-Toledo International Inc. (NYSE: MTD) announced today that Pablo Perversi has been appointed to its Board of Directors, effective November 6, 2025. Mr. Perversi is the President of Europe at Danone, a leading global food and beverage company, and a member of its Executive Committee. Prior to his current role, Pablo served as Chief Innovation, Quality, and Sustainability Officer and President of Gourmet Division for Barry Callebaut from 2017 to 2022. Before that, he held various roles of increasing responsibility at Unilever from 1993 to 2017, his last position there being Vice President of Foods Europe. Roland Diggelmann, Chair of the Board, stated, 'Pablo is a very accomplished leader of global organizations in the food industry, an important market for METTLER TOLEDO. His wealth of experience from over 30 years of leadership at branded food companies across Europe, Latin America, and Asia will provide valuable perspectives to our business. We welcome Pablo and look forward to his contributions to our Board.' METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Globe and Mail

time4 hours ago

  • Globe and Mail

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, with many large drugmakers like Pfizer PFE, Eli Lilly LLY, Amgen AMGN, Gilead Sciences GILD and Novo Nordisk NVO, among others, due to announce results. The earnings season for the sector kicked off around mid-July when Johnson & Johnson reported solid second-quarter results, beating estimates for both earnings and sales. Novartis and Bristol Myers followed suit, beating second-quarter estimates for both earnings and revenues. Merck beat estimates for earnings while meeting the same for revenues in the second quarter. Meanwhile, AstraZeneca met estimates for earnings while beating the same for revenues in the second quarter. French drugmaker Sanofi came out with disappointing second-quarter results as it missed estimates for both earnings and sales. Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies. Per the Earnings Trends report, as of July 29, 33.3% of the companies in the Medical sector — representing 40.9% of the sector's market capitalization — reported quarterly earnings. Out of these, 80% surpassed earnings estimates, while 95% beat the same for revenues. Earnings declined 10.4% year over year, while revenues rose 11.9%. Overall, second-quarter earnings of the Medical sector are expected to remain flat, while sales are projected to rise 8.7% from the year-ago quarter. Let's see how things have shaped up for these companies ahead of their earnings announcements. Pfizer PFE's performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 43.49%, on average. In the last reported quarter, the company delivered an earnings surprise of 43.75%. The Zacks Consensus Estimate for second-quarter sales and earnings stands at $13.78 billion and 58 cents per share, respectively. Pfizer has an Earnings ESP of +1.43% and a Zacks Rank #3 (Hold), indicating a beat this time around. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Higher sales of Pfizer's products like Vyndaqel family, Padcev, Lorbrena and Nurtec are expected to have offset softer sales of some key products like Prevnar, Xeljanz, Eliquis and Ibrance in the second quarter. The Medicare Part D redesign under the Inflation Reduction Act (IRA) is likely to have impacted U.S. revenues, particularly sales of higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE is scheduled to report second-quarter results on Aug. 5, before the opening bell. Pfizer Inc. Price and EPS Surprise Eli Lilly LLY's performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the remaining two occasions. It delivered a four-quarter earnings surprise of 6.69%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 5.11%. The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively. LLY has an Earnings ESP of +0.18% and a Zacks Rank #3, indicating a positive earnings surprise this time around. In the second quarter, Lilly's top-line growth is likely to have been driven by its popular GLP-1 drugs, diabetes drug Mounjaro and weight loss medicine, Zepbound, driven by high demand trends. Higher demand and volume growth for Lilly's other key drugs like Emgality, Jardiance, Olumiant, Taltz and Verzenio are likely to have provided top-line support in the second quarter, driven by increased demand trends. LLY is scheduled to report second-quarter results on Aug. 7, before the opening bell. Amgen AMGN's performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 8.34%, on average. In the last reported quarter, the company delivered an earnings surprise of 17.79%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $8.86 billion and $5.26 per share, respectively. AMGN has an Earnings ESP of +0.56% and a Zacks Rank #3, indicating a positive surprise this time around. Amgen's product sales in the second quarter are likely to have been driven by strong volume growth of products like Evenity, Repatha and Blincyto, among others. However, prices of most products are expected to have declined due to higher rebates to support expanded access. Higher volumes of newer drugs like Tezspire and Tavneos are also expected to have contributed to top-line growth, driven by an increase in new patient volume. AMGN is scheduled to report second-quarter results on Aug. 5, after market close. Gilead Sciences GILD's performance has been mixed, with earnings beating estimates in three of the trailing four quarters and missing the same on the remaining occasion. The company delivered a four-quarter earnings surprise of 16.48%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 0.55%. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $6.95 billion and $1.95 per share, respectively. GILD has an Earnings ESP of +0.58% and a Zacks Rank #3, indicating a positive surprise this time around. Gilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. HIV sales were up in the first quarter despite the impact of the new Medicare Part D model implementation due to increased demand for Biktarvy and Descovy. This trend has most likely prevailed in the second quarter as well. Higher demand for viral hepatitis medicines has likely boosted sales of the Liver Disease portfolio in the second quarter. GILD is scheduled to report second-quarter results on Aug. 7, after market close. Novo Nordisk NVO's performance has been mixed, with earnings beating estimates in one of the trailing four quarters, meeting the same once and missing the same on the remaining two occasions. The company delivered a four-quarter earnings surprise of 0.02%, on average. In the last reported quarter, the company delivered in-line earnings. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $11.79 billion and 93 cents per share, respectively. NVO has an Earnings ESP of +0.22% and a Zacks Rank #4 (Sell). Last week, NVO lowered its 2025 outlook for both sales and operating profit growth. The company expects sales to rise 8-14% in 2025, down from its earlier forecast of 13-21%. Similarly, it revised its operating profit growth projection to 10-16%, down from the prior range of 16-24%. NVO cited weaker-than-expected momentum in key markets for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, as reasons for the guidance cut. Also, during the same time, Novo Nordisk reported preliminary earnings per American Depositary Receipt of 91 cents (DKK 5.96), which missed the Zacks Consensus Estimate of 94 cents. The company said its sales for the second quarter have increased 18% at a constant exchange rate. Novo Nordisk is set to release results on Aug. 6, before the opening bell. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store